Top 3 UK Stocks Estimated Below Fair Value In July 2026
As the FTSE 100 and FTSE 250 indices face pressure from weak global cues, particularly due to faltering trade data from China, investors are closely watching how these developments impact UK markets. In such a climate, identifying stocks that are estimated to be below their fair value can offer potential opportunities for those looking to navigate the current economic challenges.
Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Rosebank Industries (LSE:ROSE) | £2.95 | £5.50 | 46.4% |
| RHI Magnesita (LSE:RHIM) | £29.55 | £58.93 | 49.9% |
| Living REIT (LSE:LIVE) | £0.787 | £1.56 | 49.5% |
| Kistos Holdings (AIM:KIST) | £2.77 | £5.35 | 48.2% |
| Eurocell (LSE:ECEL) | £1.13 | £2.19 | 48.3% |
| Entain (LSE:ENT) | £5.588 | £10.91 | 48.8% |
| CVS Group (LSE:CVSG) | £12.84 | £23.84 | 46.1% |
| AstraZeneca (LSE:AZN) | £125.94 | £226.89 | 44.5% |
| Advanced Medical Solutions Group (AIM:AMS) | £2.79 | £5.02 | 44.4% |
| Accsys Technologies (AIM:AXS) | £0.745 | £1.44 | 48.1% |
Here's a peek at a few of the choices from the screener.
CVS Group (LSE:CVSG)
Overview: CVS Group plc operates veterinary services, an online pharmacy, and retail businesses in the United Kingdom and Australia, with a market cap of £885.14 million.
Operations: The company's revenue is primarily generated from its veterinary practices (£632.70 million), laboratories (£33 million), and online retail business (£47.90 million).
Estimated Discount To Fair Value: 46.1%
CVS Group is trading at £12.84, significantly below its estimated future cash flow value of £23.84, suggesting undervaluation based on cash flows. Analysts forecast significant earnings growth of 23.38% annually over the next three years, surpassing the UK market average growth rate. Despite a high debt level and low projected return on equity (14.5%), CVS has initiated a £50 million share buyback to enhance shareholder value and address perceived undervaluation concerns highlighted by activist investors like Converium Capital Inc.
- The growth report we've compiled suggests that CVS Group's future prospects could be on the up.
- Click here to discover the nuances of CVS Group with our detailed financial health report.
Living REIT (LSE:LIVE)
Overview: Living REIT plc is a Real Estate Investment Trust based in England and Wales, focusing on property investments, with a market cap of £309.66 million.
Operations: The company's revenue is primarily derived from its residential real estate segment, generating £40.77 million.
Estimated Discount To Fair Value: 49.5%
Living REIT, trading at £0.79, is valued significantly below its estimated future cash flow value of £1.56, indicating potential undervaluation based on cash flows. Analysts forecast robust earnings growth of 48.3% annually over the next three years, outpacing the UK market average. Despite this positive outlook, return on equity is expected to remain low at 7.4%, and debt levels are not well covered by operating cash flow, posing financial challenges for the company.
- Our growth report here indicates Living REIT may be poised for an improving outlook.
- Click to explore a detailed breakdown of our findings in Living REIT's balance sheet health report.
M&G (LSE:MNG)
Overview: M&G plc, with a market cap of £8.43 billion, offers investment and savings products to both institutional clients and individual policyholders in the United Kingdom and internationally through its subsidiaries.
Operations: M&G plc generates revenue through two primary segments: Asset Management, contributing £4.59 billion, and Life (including Wealth), contributing £899 million.
Estimated Discount To Fair Value: 41.3%
M&G, currently priced at £3.54, is trading well below its estimated future cash flow value of £6.03, highlighting a potential undervaluation. Despite anticipated earnings growth of 27.5% annually over the next three years, which exceeds the UK market average, revenue is expected to decline significantly by 66% per year. The dividend yield of 5.79% lacks coverage by earnings and debt levels are not adequately supported by operating cash flow.
- According our earnings growth report, there's an indication that M&G might be ready to expand.
- Take a closer look at M&G's balance sheet health here in our report.
Turning Ideas Into Actions
- Explore the 40 names from our Undervalued UK Stocks Based On Cash Flows screener here.
- Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com